Subscribe

Personalized Medicine in Rheumatology

Clinicians may be able to use the multibiomarker disease activity (MBDA) score to predict rheumatoid arthritis (RA) flares within a year of discontinuation of tumor necrosis factor inhibitor (TNFi).
The multibiomarker disease activity (MBDA) scale appears to be a very versatile tool, based on results presented at the 2015 annual meeting of the American College of Rheumatology.
The versatile multibiomarker disease activity (MBDA) score may be able to predict rheumatoid arthritis (RA) relapse within the first year of tapering disease-modifying antirheumatic drug (DMARD) treatment.
Autoantibodies are a key feature of rheumatoid arthritis (RA) and a useful marker in the diagnosis and classification of the disease, as well as to determine its severity and development.
Paris, France—Progress in genotyping patients with rheumatoid arthritis (RA) suggests that the amino acid valine at position 11 of the HLA-DRB1 gene appears to be the strongest independent genetic determinant of radiographic damage in this disease.
A recent review evaluating currently available data on rheumatoid arthritis (RA) diagnosis, prognosis, and prediction of response to therapy, highlights the potential of gene expression profiling in understanding RA biology, patient management, and personalized care.
A newly developed plasma cell (PC) 5-gene signature accurately measures PC levels in patients with scleroderma and other autoimmune diseases, including lupus and rheumatoid arthritis (RA).
A previously unknown locus for rheumatoid arthritis (RA) susceptibility has been identified by researchers from the United Kingdom involved in the genome-wide association studies (GWAS), according to a recent study.
By Phoebe Starr San Diego, CA—“This is an exciting time for treatment of rheumatoid arthritis [RA], with many new therapies. But the question is where do we go from here for future therapies, and what have we learned from past failures,” Arthur F. Kavanaugh, MD, Director, Center for Innovative Therapy, University of California, San Diego, La Jolla, told listeners at the 2013 American College of Rheumatology meeting.
By Phoebe Starr San Diego, CA—The dysregulation of angiogenic factors early in pregnancy may pave the way for a test to predict poor pregnancy outcomes in women with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS), according to a study presented at the 2013 American College of Rheumatology meeting.
Page 1 of 3
Results 1 - 10 of 23
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology